定量HBcrAg和HBcAb對比HBsAg和HBV DNA預測慢性乙型肝炎患者的肝纖

StephenW

Quantitative HBcrAg and HBcAb versus HBsAg and HBV DNA in predicting liver fibrosis levels of chronic hepatitis B patientsHBcrAg y HBcAb cuantitativos versus HBsAg y ADN del VHB en la predicción de los niveles de fibrosis hepática de los pacientes con hepatitis B crónica
Author links open overlay panelZhan-qingZhanga
Bi-shengShibWeiLuaDan-pingLiuaDanHuangaYan-lingFengc
https://doi.org/10.1016/j.gastrohep.2020.03.017
Get rights and content
Abstract
Objective

To evaluate the performance of the quantitative markers of hepatitis B core-related antigen (HBcrAg) and anti-hepatitis B core antigen antibodies HbcAb versus hepatitis B surface antigen (HBsAg) and hepatitis B virus DNA (HBV DNA) in predicting liver fibrosis levels in chronic hepatitis B patients.
Methods

Two hundred and fifty hepatitis B e antigen (HBeAg)-positive and 245 HBeAg-negative patients were enrolled. With reference to the Scheuer standard, stage 2 or higher and stage 4 liver disease were defined as significant fibrosis and cirrhosis, respectively. A receiver operating characteristic (ROC) curve was used to evaluate the performance of the HBV markers investigated.
Results

The areas under the ROC curves (AUCs) of HBcrAg in predicting significant fibrosis and cirrhosis in HBeAg-positive patients (0.577 and 0.700) were both close to those of HBsAg (0.617 and 0.762) (both P > 0.05). In HBeAg-negative patients (0.797 and 0.837), they were both significantly greater than those of HBV DNA (0.723 and 0.738) (P = 0.0090 and P = 0.0079). The AUCs of HBcAb in predicting significant fibrosis and cirrhosis in HBeAg-positive patients (0.640 and 0.665) were both close to those of HBsAg. In HBeAg-negative patients (0.570 and 0.621), they were both significantly less than those of HBcrAg (P < 0.0001 and P = 0.0001). Specificity in predicting significant fibrosis and sensitivity in predicting cirrhosis in HBeAg-positive patients, using a single cut-off of HBsAg ≤5,000 IU/ml, were 76.5% and 72.7%, respectively. In HBeAg-negative patients, using a single cut-off of HBcrAg >80kU/ml, they were 85.9% and 81.3%, respectively.
Conclusions

HBsAg has good performance in predicting liver fibrosis levels in HBeAg-positive and HBeAg-negative patients, and HBcrAg has very good performance in predicting liver fibrosis levels in HBeAg-negative patients.
Resumen

StephenW

定量HBcrAg和HBcAb對比HBsAg和HBV DNA預測慢性乙型肝炎患者的肝纖維化水平
作者鏈接打開覆蓋面板Zhan-qingZhanga
畢生志魏衛六旦平六旦黃a炎嶺
https://doi.org/10.1016/j.gastrohep.2020.03.017
獲取權利和內容
抽象
目的

評估乙型肝炎核心相關抗原（HBcrAg）和抗乙型肝炎核心抗原抗體HbcAb與乙型肝炎表面抗原（HBsAg）和乙型肝炎病毒DNA（HBV DNA）的定量指標在預測肝纖維化水平中的作用。慢性乙型肝炎患者。
方法

招募了250例乙型肝炎e抗原（HBeAg）陽性和245例HBeAg陰性的患者。參照Scheuer標準，將2級以上或4級肝病分別定義為明顯的纖維化和肝硬化。使用接收器工作特性（ROC）曲線評估所研究的HBV標記物的性能。
結果

HBcrAg的ROC曲線下面積（AUCs）可預測HBeAg陽性患者的顯著纖維化和肝硬化（0.577和0.700）均接近HBsAg（0.617和0.762）（P> 0.05）。在HBeAg陰性患者（0.797和0.837）中，它們均顯著大於HBV DNA（0.723和0.738）（P = 0.0090和P = 0.0079）。 HBcAb的AUC預測HBeAg陽性患者有明顯的纖維化和肝硬化（0.640和0.665）均與HBsAg接近。在HBeAg陰性患者（0.570和0.621）中，它們均顯著低於HBcrAg患者（P <0.0001和P = 0.0001）。使用HBsAg≤5,000 IU / ml的單一截斷值，預測HBeAg陽性患者的顯著纖維化的特異性和預測肝硬化的敏感性分別為76.5％和72.7％。在HBeAg陰性患者中，使用單次截留HBcrAg> 80kU / ml的患者，分別為85.9％和81.3％。
結論

HBsAg在預測HBeAg陽性和HBeAg陰性患者的肝纖維化水平方面表現良好，而HBcrAg在預測HBeAg陰性患者的肝纖維化水平方面具有很好的表現。